JP2023033129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023033129A5 JP2023033129A5 JP2022113835A JP2022113835A JP2023033129A5 JP 2023033129 A5 JP2023033129 A5 JP 2023033129A5 JP 2022113835 A JP2022113835 A JP 2022113835A JP 2022113835 A JP2022113835 A JP 2022113835A JP 2023033129 A5 JP2023033129 A5 JP 2023033129A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pharmaceutically acceptable
- formula
- narcolepsy
- mchr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 12
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 claims 11
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 4
- 206010041349 Somnolence Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 208000035959 Narcolepsy type 1 Diseases 0.000 claims 3
- 208000033409 Narcolepsy type 2 Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 201000003631 narcolepsy Diseases 0.000 claims 3
- 208000004461 narcolepsy 1 Diseases 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 claims 2
- 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 claims 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- MWULMTACIBZPGN-UHFFFAOYSA-N gw-803,430 Chemical compound COC1=CC(N2C(C=3SC(=CC=3N=C2)C=2C=CC(Cl)=CC=2)=O)=CC=C1OCCN1CCCC1 MWULMTACIBZPGN-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229960005489 paracetamol Drugs 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- IBDOVKSLMMFQPJ-IUPOGUASSA-N 1-[2-[(4ar,11r,11as)-11-methyl-9-(trifluoromethyl)-1,3,4,4a,5,6,11,11a-octahydropyrido[4,3-b]carbazol-2-yl]ethyl]cyclohexane-1-carboxylic acid;benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.C([C@@H]1[C@H](C=2C3=CC(=CC=C3NC=2C[C@H]1CC1)C(F)(F)F)C)N1CCC1(C(O)=O)CCCCC1 IBDOVKSLMMFQPJ-IUPOGUASSA-N 0.000 claims 1
- -1 ATC-0065 Chemical compound 0.000 claims 1
- BKKPIQPFRAPEAY-UHFFFAOYSA-N AZD1979 Chemical compound C1=CC(OC)=CC=C1C1=NN=C(C(=O)N2CC(C2)OC=2C=CC(CN3CC4(COC4)C3)=CC=2)O1 BKKPIQPFRAPEAY-UHFFFAOYSA-N 0.000 claims 1
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 229940123576 Acetyltransferase inhibitor Drugs 0.000 claims 1
- 208000009575 Angelman syndrome Diseases 0.000 claims 1
- 102000006809 Arylamine N-Acetyltransferase Human genes 0.000 claims 1
- 108020005224 Arylamine N-acetyltransferase Proteins 0.000 claims 1
- 206010003628 Atonic seizures Diseases 0.000 claims 1
- 208000003417 Central Sleep Apnea Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims 1
- 102000044674 Melanin-concentrating hormone receptor 1 Human genes 0.000 claims 1
- YDTUJCNTIMWHPJ-NRFANRHFSA-N [(1r)-2-[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3-yl]-2-methoxyphenoxy]-1-cyclopropylethyl] dihydrogen phosphate Chemical compound C1([C@@H](OP(O)(O)=O)COC2=CC=C(C=C2OC)N2C(C=3SC(=CC=3N=C2)C=2C=CC(Cl)=CC=2)=O)CC1 YDTUJCNTIMWHPJ-NRFANRHFSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- FAIMGWSOSCFGRU-IYBDPMFKSA-N chembl182150 Chemical compound N([C@H]1CC[C@H](CC1)NC=1N=C(C2=CC=CC=C2N=1)N(C)C)C(=O)C1=CC=C(F)C(F)=C1 FAIMGWSOSCFGRU-IYBDPMFKSA-N 0.000 claims 1
- 208000012696 congenital leptin deficiency Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000002267 hypothalamic effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- FWMHZWMPUWAUPL-NDEPHWFRSA-N methyl (4s)-3-[3-[4-(3-acetamidophenyl)piperidin-1-yl]propylcarbamoyl]-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,4-dihydropyrimidine-5-carboxylate Chemical compound N1([C@H](C(=C(NC1=O)COC)C(=O)OC)C=1C=C(F)C(F)=CC=1)C(=O)NCCCN(CC1)CCC1C1=CC=CC(NC(C)=O)=C1 FWMHZWMPUWAUPL-NDEPHWFRSA-N 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 208000001022 morbid obesity Diseases 0.000 claims 1
- 208000028511 narcolepsy without cataplexy Diseases 0.000 claims 1
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 claims 1
- VAKYVNYLCIABRV-UHFFFAOYSA-N ngd-4715 Chemical compound C1=C(OC)C(OC)=CC=C1CN1CCN(C=2N=C(OC)C(Br)=CC=2)CC1 VAKYVNYLCIABRV-UHFFFAOYSA-N 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 229940072647 panadol Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025094423A JP2025120306A (ja) | 2020-01-10 | 2025-06-05 | 薬物の治療的組み合わせ及びそれらの使用方法 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959769P | 2020-01-10 | 2020-01-10 | |
| US202062959534P | 2020-01-10 | 2020-01-10 | |
| US62/959,769 | 2020-01-10 | ||
| US62/959,534 | 2020-01-10 | ||
| US202062980053P | 2020-02-21 | 2020-02-21 | |
| US62/980,053 | 2020-02-21 | ||
| US202063022484P | 2020-05-09 | 2020-05-09 | |
| US63/022,484 | 2020-05-09 | ||
| PCT/US2021/012869 WO2021142395A1 (en) | 2020-01-10 | 2021-01-10 | Therapeutic combinations of drugs and methods of using them |
| JP2022542390A JP2023509800A (ja) | 2020-01-10 | 2021-01-10 | 薬物の治療的組み合わせ及びそれらの使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542390A Division JP2023509800A (ja) | 2020-01-10 | 2021-01-10 | 薬物の治療的組み合わせ及びそれらの使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025094423A Division JP2025120306A (ja) | 2020-01-10 | 2025-06-05 | 薬物の治療的組み合わせ及びそれらの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023033129A JP2023033129A (ja) | 2023-03-09 |
| JP2023033129A5 true JP2023033129A5 (https=) | 2024-01-18 |
Family
ID=76788320
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542390A Pending JP2023509800A (ja) | 2020-01-10 | 2021-01-10 | 薬物の治療的組み合わせ及びそれらの使用方法 |
| JP2022113835A Pending JP2023033129A (ja) | 2020-01-10 | 2022-07-15 | 薬物の治療的組み合わせ及びそれらの使用方法 |
| JP2025094423A Pending JP2025120306A (ja) | 2020-01-10 | 2025-06-05 | 薬物の治療的組み合わせ及びそれらの使用方法 |
| JP2025114768A Pending JP2025137534A (ja) | 2020-01-10 | 2025-07-07 | 薬物の治療的組み合わせ及びそれらの使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542390A Pending JP2023509800A (ja) | 2020-01-10 | 2021-01-10 | 薬物の治療的組み合わせ及びそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025094423A Pending JP2025120306A (ja) | 2020-01-10 | 2025-06-05 | 薬物の治療的組み合わせ及びそれらの使用方法 |
| JP2025114768A Pending JP2025137534A (ja) | 2020-01-10 | 2025-07-07 | 薬物の治療的組み合わせ及びそれらの使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20230084144A1 (https=) |
| EP (2) | EP4076527A4 (https=) |
| JP (4) | JP2023509800A (https=) |
| CN (3) | CN115304595A (https=) |
| AU (1) | AU2021206286A1 (https=) |
| WO (1) | WO2021142395A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP2200222A1 (hu) * | 2022-06-17 | 2023-12-28 | Richter Gedeon Nyrt | MCHR1 antagonisták a Prader-Willi szindróma kezelésére |
| CN119925562B (zh) * | 2023-11-03 | 2025-11-28 | 中国科学院上海药物研究所 | 趋化因子受体2拮抗剂在制备治疗糖尿病并发焦虑症的应用 |
| CN117379427A (zh) * | 2023-11-08 | 2024-01-12 | 厦门市儿童医院(复旦大学附属儿科医院厦门医院) | 化合物THBXM在制备THR-β激动剂中的应用 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1299362A4 (en) * | 2000-07-05 | 2004-11-03 | Synaptic Pharma Corp | SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE |
| JP2004518709A (ja) | 2001-02-13 | 2004-06-24 | アストラゼネカ・アクチエボラーグ | 新規放出修飾製剤 |
| US6809104B2 (en) * | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
| CN1662231A (zh) * | 2002-04-24 | 2005-08-31 | 柏树生物科学公司 | 包括应激相关障碍在内的功能性躯体障碍的预防与治疗 |
| DE10250084A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US8906413B2 (en) | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
| AU2004249172A1 (en) | 2003-06-24 | 2004-12-29 | Baxter International Inc. | Specific delivery of drugs to the brain |
| JP2007509158A (ja) * | 2003-10-23 | 2007-04-12 | グラクソ グループ リミテッド | 肥満、糖尿病、うつ病及び不安を治療するためのｍｃｈｒ１アンタゴニストとしての３−（４−アミノフェニル）チエノピリミド−４−オン誘導体 |
| CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
| TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
| UY30378A1 (es) * | 2006-06-02 | 2008-01-02 | Janssen Pharmaceutica Nv | Nuevos derivados de piridinona n-aril y n-heteroaril sustituidos para usar en enfermedades mediadas por mch-1 |
| EP2102208B1 (en) * | 2006-12-05 | 2014-04-23 | Janssen Pharmaceutica NV | Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases |
| ES2660173T3 (es) * | 2007-01-16 | 2018-03-21 | Ipintl, Llc | Nueva composición para el tratamiento del síndrome metabólico |
| US7846930B2 (en) * | 2007-05-18 | 2010-12-07 | Janssen Pharmaceutica Nv | Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators |
| KR101614723B1 (ko) * | 2008-01-11 | 2016-04-22 | 알바니 몰레큘라 리써치, 인크. | Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌 |
| PE20091928A1 (es) * | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
| SA110310332B1 (ar) * | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| WO2010132437A1 (en) * | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| AU2010247763B2 (en) * | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| AU2010247735B2 (en) * | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
| KR20120060207A (ko) * | 2009-08-26 | 2012-06-11 | 사노피 | 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도 |
| TW201402556A (zh) * | 2012-05-30 | 2014-01-16 | Toyama Chemical Co Ltd | 氘化含氮雜環羧醯胺衍生物或其鹽 |
| US9499482B2 (en) * | 2012-09-05 | 2016-11-22 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
| JP6146990B2 (ja) * | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたｃｆｔｒ増強物質 |
| US20140364367A1 (en) * | 2013-06-08 | 2014-12-11 | Sedogen, Llc | Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener |
| JP6367545B2 (ja) * | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| WO2017121432A1 (en) * | 2016-01-15 | 2017-07-20 | Saniona A/S | Tesofensine and metoprolol for treatment of hypertension |
| MX2021008208A (es) * | 2019-01-07 | 2021-11-17 | Saniona As | Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. |
-
2021
- 2021-01-10 EP EP21738983.2A patent/EP4076527A4/en active Pending
- 2021-01-10 EP EP22188840.7A patent/EP4151210A3/en active Pending
- 2021-01-10 CN CN202210965369.0A patent/CN115304595A/zh active Pending
- 2021-01-10 US US17/793,037 patent/US20230084144A1/en active Pending
- 2021-01-10 CN CN202210965451.3A patent/CN115350184A/zh active Pending
- 2021-01-10 JP JP2022542390A patent/JP2023509800A/ja active Pending
- 2021-01-10 AU AU2021206286A patent/AU2021206286A1/en active Pending
- 2021-01-10 WO PCT/US2021/012869 patent/WO2021142395A1/en not_active Ceased
- 2021-01-10 CN CN202180008853.8A patent/CN115884790A/zh active Pending
-
2022
- 2022-07-08 US US17/860,539 patent/US20230002377A1/en active Pending
- 2022-07-15 JP JP2022113835A patent/JP2023033129A/ja active Pending
-
2025
- 2025-06-05 JP JP2025094423A patent/JP2025120306A/ja active Pending
- 2025-07-07 JP JP2025114768A patent/JP2025137534A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023033129A5 (https=) | ||
| JP3432823B2 (ja) | 新規の有効な末端分化誘発剤およびその使用方法 | |
| RU2121998C1 (ru) | Производные пиримидина, способ их получения, фармкомпозиция | |
| JP5531370B2 (ja) | プロスタグランジンｄ２受容体のアンタゴニスト | |
| RU2186763C2 (ru) | Амидные производные или их соли | |
| JP6572392B2 (ja) | 電位作動型ナトリウムチャネルにおいて選択的活性を有する、ヒドロキシアルキルアミンおよびヒドロキシシクロアルキルアミンで置換されたジアミン−アリールスルホンアミド化合物 | |
| JP2022120072A (ja) | ヒストンアセチルトランスフェラーゼ活性化剤及び組成物並びにそれらの使用 | |
| US9676708B2 (en) | Controlled HNO release through intramolecular cyclization-elimination | |
| JP3179599B2 (ja) | 縮合ベンゼンオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤 | |
| EA002763B1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| US20050165114A1 (en) | Benzene derivatives and pharmaceutical use thereof | |
| JP6363164B2 (ja) | ヒストンデアセチラーゼ阻害剤及びその組成物と使用方法 | |
| JP2016513076A5 (https=) | ||
| EA026702B1 (ru) | Производные анилина, их получение и терапевтическое применение | |
| KR100629628B1 (ko) | 치환된 2-벤질아미노-2-페닐-아세트아미드 화합물 및 이를 포함하는 약제학적 조성물 | |
| US20210363110A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| JP3542599B2 (ja) | 置換（アリールアルコキシベンジル）アミノプロパンアミド誘導体及びその製造方法 | |
| BR112020016784A2 (pt) | Composto de di-hidropirimidinona ou di-hidropirimidinona condensado ao anel saturado e uso farmacêutico do mesmo | |
| US20050032747A1 (en) | COX-2 and FAAH inhibitors | |
| CN110372593A (zh) | 大麻素受体拮抗剂/反向激动剂 | |
| JP2002514621A (ja) | 置換グアニジン及びジアミノニトロエテン、それらの製造及び使用 | |
| US20050288369A1 (en) | Novel n-hydroxy thiourea, urea and amide compounds and the pharmaceutical compositions comprising the same | |
| JP2004534776A (ja) | Ｃｏｘ−２選択的阻害剤としてのピリミジン誘導体 | |
| KR20220034853A (ko) | 인터류킨의 조정에서의 전구약물 | |
| FR2845384A1 (fr) | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |